{
    "data": [
        {
            "id": "69038c46ecb8a70001459cb4",
            "title": "Bitcoin Sells Trump-Xi Deal, Fed Rate Cut: Is A Breakdown To $93,000 Next?",
            "description": "<div><div class=\"sc-fxwyg khStwV\"><!--$--><p class=\"block core-block\"><strong>Bitcoin </strong>(CRYPTO: <a class=\"ticker\" href=\"https://www.benzinga.com/quote/btc/usd\" target=\"_blank\">BTC</a>) is trading below $108,000 after the Federal Reserve's 25-basis-point rate cut failed to lift markets, with charts <a href=\"https://www.benzinga.com/money/bitcoin-price-prediction-oct-14\" target=\"_blank\">pointing to deeper losses</a>.</p><!--/$--><!--$--><h3 class=\"wp-block-heading\">Fed Rate Cut Fails To Wake Up Bitcoin Price</h3><!--/$--><!--$--><div class=\"min-w-[300px] w-[300px] min-h-[250px] raptive-ad-placement mx-auto overflow-hidden min-w-[300px]\"></div><!--/$--><!--$--><p class=\"block core-block\">The Federal Reserve reduced interest rates by 25 basis points to a range of 3.75%–4.00%, marking its first cut in months. </p><!--/$--><!--$--><p class=\"block core-block\">The move, widely expected, reflected policymakers attempt to balance slowing inflation with emerging economic weakness. </p><!--/$--><!--$--><p class=\"block core-block\">Despite the policy shift, markets barely <a href=\"https://x.com/Cointelegraph/status/1983700432145793098\" target=\"_blank\">reacted</a>, as traders had already priced in the decision ahead of Wednesday's announcement.</p><!--/$--><!--$--><p class=\"block core-block\">Analysts said the muted response stemmed from expectations that the Fed would act cautiously through year-end. </p><!--/$--><!--$--><div class=\"sc-eQzVdq kfhAgV\"></div><!--/$--><!--$--><p class=\"block core-block\">U.S. equities traded mixed, with the <strong>S&amp;P 500</strong> (NYSE:<a class=\"ticker\" href=\"https://www.benzinga.com/quote/SPY\" target=\"_blank\">SPY</a>) flat at 6,890, <strong>Dow Jones</strong> slipping 0.16%, and the <strong>Nasdaq Composite</strong> up 0.55%.</p><!--/$--><!--$--><p class=\"block core-block\">10-year Treasury yields edged to 4.10% and the global crypto market cap fell 4.2% to $3.64 trillion.</p><!--/$--><!--$--><h3 class=\"wp-block-heading\">Powell's Warning Rattles Markets And Crypto Traders</h3><!--/$--><!--$--><p class=\"block core-block\">Following the meeting, Fed Chair <strong>Jerome Powell</strong> emphasized that another rate cut in December \"is not a foregone conclusion,\" highlighting deep divisions within the Federal Open Market Committee.</p><!--/$--><!--$--><div class=\"nativo-placement-in-content-ap\"></div><!--/$--><!--$--><p class=\"block core-block\">In a post on X, <strong>Quinn Thompson</strong>, chief investment officer at <strong>Lekker Capital</strong>, <a href=\"https://x.com/qthomp/status/1983656245371531553\" target=\"_blank\">described</a> Powell's language as \"political posturing\" aimed at pushing the administration to reopen the government. </p><!--/$--><!--$--><p class=\"block core-block\">Thompson argued that Powell's message effectively warned that a continued shutdown could block key economic data and hinder future rate decisions.</p><!--/$--><!--$--><p class=\"block core-block\">The shift in tone rattled markets briefly, with Treasury yields climbing and the probability of a December cut falling from near certainty to roughly even odds. </p><!--/$--><!--$--><div class=\"min-w-[300px] w-[300px] min-h-[250px] raptive-ad-placement mx-auto overflow-hidden min-w-[300px]\"></div><!--/$--><!--$--><p class=\"block core-block\">Crypto assets mirrored the cautious sentiment, with <strong>Ethereum </strong>(CRYPTO: <a class=\"ticker\" href=\"https://www.benzinga.com/quote/eth/usd\" target=\"_blank\">ETH</a>) down to $3,773 and <strong>XRP</strong> (CRYPTO: <a class=\"ticker\" href=\"https://www.benzinga.com/quote/xrp/usd\" target=\"_blank\">XRP</a>) slipping to $2.45.</p><!--/$--><!--$--><h3 class=\"wp-block-heading\">Liquidity Shift Could Be Hidden Bullish Fuel For Bitcoin</h3><!--/$--><!--$--><p class=\"block core-block\">Thompson said Powell's comments should not be viewed as a hawkish turn but as leverage in a political negotiation. </p><!--/$--><!--$--><div class=\"min-w-[300px] w-[300px] min-h-[250px] raptive-ad-placement mx-auto overflow-hidden min-w-[300px]\"></div><!--/$--><!--$--><p class=\"block core-block\">He noted that the Fed will halt its quantitative tightening program on Dec. 1, ending the runoff of Treasury and mortgage holdings. </p><!--/$--><!--$--><p class=\"block core-block\">Instead, the central bank will reinvest maturing securities into Treasury bills, which he framed as \"incrementally liquidity positive.\"</p><!--/$--><!--$--><p class=\"block core-block\">Analysts see that as a supportive signal for risk assets, especially cryptocurrencies, which tend to benefit from easier dollar liquidity. </p><!--/$--><!--$--><p class=\"block core-block\">The mix of cooling inflation, labor-market softness, and a pause in balance-sheet contraction creates an environment historically favorable for digital assets.</p><!--/$--><!--$--><h3 class=\"wp-block-heading\">Bitcoin Price Breakdown Puts $93,000 Support In The Spotlight</h3><!--/$--><!--$--><!--/$--><!--$--><p class=\"block core-block\"><a href=\"https://in.tradingview.com/symbols/BTCUSD/\" target=\"_blank\"><em>BTC Price Action (Source: TradingView)</em></a></p><!--/$--><!--$--><p class=\"block core-block\">On the charts, bitcoin has slipped under $108,000, breaking down from a multi-week symmetrical triangle. </p><!--/$--><!--$--><p class=\"block core-block\">The rejection near the EMA cluster between $111,700 and $112,900 confirmed selling pressure. </p><!--/$--><!--$--><p class=\"block core-block\">Momentum remains weak, with the RSI near 30, suggesting the asset is approaching oversold conditions but not yet primed for reversal.</p><!--/$--><!--$--><p class=\"block core-block\">The next major support sits at $102,000–$100,000, followed by a critical zone around $93,000–$92,000 — the final major base from August. </p><!--/$--><!--$--><p class=\"block core-block\">A failure to defend this area could expose Bitcoin to deeper losses toward $90,000. </p><!--/$--><!--$--><p class=\"block core-block\">Bulls would need a recovery above $112,000 to neutralize the breakdown and restore short-term momentum.</p><!--/$--><!--$--><div><div><div class=\"bz-campaign bz-campaign-bottom-48534555\" data-nosnippet=\"true\"><div class=\"sc-c014f608-0 kUPEDz skeleton min-h-[inherit] animate-pulse variant\" role=\"status\"><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div></div><div class=\"flex sm:hidden flex-col\"><div class=\"sc-c014f608-0 kUPEDz skeleton min-h-[inherit] animate-pulse variant\" role=\"status\"><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div></div></div></div></div></div><!--/$--><!--$--><!--/$--><!--$--><ul class=\"wp-block-list\">\n<li><strong><a href=\"https://www.benzinga.com/news/politics/25/10/48519309/trump-concludes-amazing-meeting-with-xi-jinping-teases-pretty-soon-trade-deal\" target=\"_blank\">Trump Concludes ‘Amazing’ Meeting With Xi Jinping, Teases ‘Pretty Soon’ Trade Deal</a></strong></li>\n</ul><!--/$--><!--$--><p class=\"block core-block\"><em>Image: Shutterstock</em></p><!--/$--></div></div>",
            "image": "https://www.benzinga.com/files/images/story/2025/10/30/A-Futuristic-Digital-themed-Illustration.jpeg",
            "link": "https://www.benzinga.com/crypto/cryptocurrency/25/10/48534555/bitcoin-sells-trump-xi-deal-fed-rate-cut-is-a-breakdown-to-93000-next",
            "pub_date": "2025-10-31 00:03:23",
            "source": "benzinga",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "69038d30ecb8a70001459d40",
            "title": "Ambev&#39;s Q3 Profit Jumps 8.7% Y/Y, Shares Gain On Higher Margins And Buyback",
            "description": "<div><div class=\"sc-fxwyg khStwV\"><!--$--><p class=\"block core-block\"><strong>Ambev SA</strong> (NYSE:<a class=\"ticker\" href=\"https://www.benzinga.com/quote/ABEV\" target=\"_blank\">ABEV</a>) shares traded higher on Thursday after the company reported <a href=\"https://www.benzinga.com/earnings\" rel=\"noreferrer noopener\" target=\"_blank\">third-quarter FY25 results</a>.</p><!--/$--><!--$--><h2 class=\"wp-block-heading\">Details</h2><!--/$--><!--$--><div class=\"min-w-[300px] w-[300px] min-h-[250px] raptive-ad-placement mx-auto overflow-hidden min-w-[300px]\"></div><!--/$--><!--$--><p class=\"block core-block\">Ambev reported quarterly earnings of 24 cents per share in Brazilian Reals (4 cents per share in USD), up 8.7% year over year (Y/Y), driven by lower taxes.</p><!--/$--><!--$--><p class=\"block core-block\">The company reported quarterly sales of 20.8 billion Brazilian Real ($3.826 billion), which declined 5.7% Y/Y.</p><!--/$--><!--$--><p class=\"block core-block\"><strong><em>Also Read: </em></strong><em><a href=\"https://www.benzinga.com/markets/commodities/25/06/45766967/us-aluminum-tariffs-risk-supply-chain-and-food-security-industry-insiders-warn\" rel=\"noreferrer noopener\" target=\"_blank\">US Aluminum Tariffs Risk Supply Chain And Food Security, Industry Insiders Warn</a></em></p><!--/$--><!--$--><div class=\"sc-SfCGz ciVbir\"></div><!--/$--><!--$--><p class=\"block core-block\">Normalized EBITDA, meanwhile, increased by 2.9% Y/Y organically, and margins expanded 50 basis points, led by disciplined cost and expense management and efficient resource allocation.</p><!--/$--><!--$--><h2 class=\"wp-block-heading\">Segment Performance</h2><!--/$--><!--$--><p class=\"block core-block\">Net revenue per hectoliter (NR/hl) grew by 7.4%, contributing to overall net revenue increases <a href=\"https://www.sec.gov/Archives/edgar/data/1565025/000129281425003688/abevpr3q25_6k.htm\" rel=\"noreferrer noopener\" target=\"_blank\">in </a>most business units: Brazil non-alcoholic beverages (NAB) rose by 0.5%, Caribbean (CAC) by 2.2% and Latin America South (LAS) by 9.2%, while Canada and Brazil Beer saw a decline of 0.1% and 2.1%, respectively, due to volume decreases.</p><!--/$--><!--$--><div class=\"nativo-placement-in-content-ap\"></div><!--/$--><!--$--><p class=\"block core-block\">Organically, volumes declined 5.8% Y/Y mainly due to unseasonable weather and a challenging environment in key markets. By Segment, volumes fell in Brazil Beer (-7.7% Y/Y), Brazil NAB (-8.6% Y/Y), Canada (-2.0% Y/Y), and LAS (-0.8% Y/Y).</p><!--/$--><!--$--><h2 class=\"wp-block-heading\">Other Key Metrics</h2><!--/$--><!--$--><p class=\"block core-block\">The Board of Directors approved a share repurchase program of up to 208 million shares, valued at about 2.5 billion Brazilian Reals based on the October 29, 2025, closing price, to be executed over the next 18 months.</p><!--/$--><!--$--><p class=\"block core-block\">As of September 30, cash and cash equivalents (less bank overdrafts) stood at 18.31 billion Brazilian Real.</p><!--/$--><!--$--><p class=\"block core-block\"><strong>Price Action:</strong> ABEV shares are up 5.28% at $2.295 at the last check on Thursday.</p><!--/$--><!--$--><div><div><div class=\"bz-campaign bz-campaign-bottom-48534693\" data-nosnippet=\"true\"><div class=\"sc-c014f608-0 kUPEDz skeleton min-h-[inherit] animate-pulse variant\" role=\"status\"><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div></div><div class=\"flex sm:hidden flex-col\"><div class=\"sc-c014f608-0 kUPEDz skeleton min-h-[inherit] animate-pulse variant\" role=\"status\"><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div></div></div></div></div></div><!--/$--><!--$--><!--/$--><!--$--><ul class=\"wp-block-list\">\n<li><strong><a href=\"https://www.benzinga.com/markets/latin-america/25/06/45937801/latin-americas-hot-stocks-3-nyse-picks-to-dodge-trade-wars-mideast-mayhem\" rel=\"noreferrer noopener\" target=\"_blank\">Latin America’s Hot Stocks: 3 NYSE Picks To Dodge Trade Wars, Mideast Mayhem</a></strong></li>\n</ul><!--/$--><!--$--><p class=\"block core-block\"><em>Photo: Shutterstock</em></p><!--/$--></div></div>",
            "image": "https://www.benzinga.com/files/images/story/2025/10/30/Ambev--SA.jpeg",
            "link": "https://www.benzinga.com/markets/earnings/25/10/48534693/ambevs-q3-profit-jumps-8-7-y-y-shares-gain-on-higher-margins-and-buyback",
            "pub_date": "2025-10-31 00:07:16",
            "source": "benzinga",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "690390d8ecb8a70001459fa1",
            "title": "Cardinal Health Rallies As Strong Start To 2026 Fuels Higher Earnings Guidance",
            "description": "<div><div class=\"sc-fxwyg khStwV\"><!--$--><p class=\"block core-block\"><strong>Cardinal Health Inc.’s </strong>(NYSE:<a class=\"ticker\" href=\"https://www.benzinga.com/quote/CAH\" target=\"_blank\">CAH</a>) stock surged on Thursday as the healthcare services company reported upbeat first-quarter 2026 earnings, with adjusted earnings of $2.55 per share, beating the <a href=\"https://www.benzinga.com/calendars/earnings\" rel=\"noreferrer noopener\" target=\"_blank\">consensus of $2.18</a>.</p><!--/$--><!--$--><p class=\"block core-block\">Sales increased 22% year over year to $64.01 billion, surpassing the consensus estimate of $59.19 billion. Adjusted operating earnings <a href=\"https://www.benzinga.com/pressreleases/25/10/n48521985/cardinal-health-reports-first-quarter-fiscal-year-2026-results-and-raises-outlook\" rel=\"noreferrer noopener\" target=\"_blank\">increased 37% to $857 million</a>.</p><!--/$--><!--$--><div class=\"min-w-[300px] w-[300px] min-h-[250px] raptive-ad-placement mx-auto overflow-hidden min-w-[300px]\"></div><!--/$--><!--$--><p class=\"block core-block\">Revenue for the Pharmaceutical and Specialty Solutions segment increased 23% to $59.2 billion, driven by growth in brand and specialty pharmaceutical sales from existing and new customers.</p><!--/$--><!--$--><p class=\"block core-block\">First quarter revenue for the Global Medical Products and Distribution segment increased 2% to $3.2 billion, driven by volume growth from existing customers.</p><!--/$--><!--$--><p class=\"block core-block\">Cardinal Health initiated a $375 million accelerated share repurchase program in the first quarter of fiscal year 2026.</p><!--/$--><!--$--><div class=\"sc-SfCGz ciVbir\"></div><!--/$--><!--$--><p class=\"block core-block\">“This outstanding first quarter reflects our focused execution across each of our operating segments and provides a solid foundation as we carry forward. As a result, we are raising our fiscal 2026 outlook,” said CEO <strong>Jason Hollar</strong>.</p><!--/$--><!--$--><h2 class=\"wp-block-heading\">Outlook</h2><!--/$--><!--$--><p class=\"block core-block\">Cardinal Health raised its outlook for fiscal year 2026 adjusted earnings per share from $9.30-$9.50 to $9.65-$9.85, above the consensus of $9.43.</p><!--/$--><!--$--><div class=\"nativo-placement-in-content-ap\"></div><!--/$--><!--$--><p class=\"block core-block\">The $0.35 increase from the prior range <span style=\"box-sizing:border-box;margin:0px;padding:0px\">reflects the company’s strong first-quarter performance and the expected contributions from the <a href=\"https://www.benzinga.com/m-a/25/08/47058401/cardinal-health-boosts-specialty-presence-with-solaris-health-acquisition-lifts-profit-outlook\" rel=\"noopener\" target=\"_blank\">Solaris Health acquisition</a></span>.</p><!--/$--><!--$--><p class=\"block core-block\">The company expects profit growth in the Pharmaceutical and Specialty Solutions segment of 16%-19%, compared to the prior guidance range of 11%-13%.</p><!--/$--><!--$--><p class=\"block core-block\">The company is also raising its expectations for adjusted free cash flow to $3.0 billion to $3.5 billion, from a prior range of $2.75 billion to $3.25 billion.</p><!--/$--><!--$--><p class=\"block core-block\"><strong>Price Action:</strong> CAH stock is trading higher by 16.55% at $191.68 at the last check on Thursday.</p><!--/$--><!--$--><!--/$--><!--$--><ul class=\"wp-block-list\">\n<li><strong><a href=\"https://www.benzinga.com/markets/tech/25/10/48520789/tesla-cybercab-to-make-apac-debut-at-chinas-annual-import-expo-in-shanghai-optimus-could-also-be-showcased\" rel=\"noreferrer noopener\" target=\"_blank\">Tesla Cybercab To Make APAC Debut At China’s Annual Import Expo In Shanghai — Optimus Could Also Be Showcased</a></strong></li>\n</ul><!--/$--><!--$--><p class=\"block core-block\"><em>Photo: Shutterstock</em></p><!--/$--><!--$--><div><div><div class=\"bz-campaign bz-campaign-bottom-48535297\" data-nosnippet=\"true\"><div class=\"sc-c014f608-0 kUPEDz skeleton min-h-[inherit] animate-pulse variant\" role=\"status\"><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div></div><div class=\"flex sm:hidden flex-col\"><div class=\"sc-c014f608-0 kUPEDz skeleton min-h-[inherit] animate-pulse variant\" role=\"status\"><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div></div></div></div></div></div><!--/$--></div></div>",
            "image": "https://www.benzinga.com/files/images/story/2025/10/30/Cardinal-Health.jpeg",
            "link": "https://www.benzinga.com/markets/earnings/25/10/48535297/cardinal-health-rallies-as-strong-start-to-2026-fuels-higher-earnings-guidance",
            "pub_date": "2025-10-31 00:22:52",
            "source": "benzinga",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "6903912decb8a70001459fc6",
            "title": "Merck Ready For Larger Than $15 Billion Deals, Raises Annual Profit Outlook",
            "description": "<div><div class=\"sc-fxwyg khStwV\"><!--$--><p class=\"block core-block\"><strong>Merck &amp; Co., Inc.</strong> (NYSE:<a class=\"ticker\" href=\"https://www.benzinga.com/quote/MRK\" target=\"_blank\">MRK</a>) stock traded in a volatile session on Thursday following its third-quarter earnings report and updated fiscal 2025 outlook.</p><!--/$--><!--$--><p class=\"block core-block\">The pharma giant reported adjusted earnings per share of $2.58, surpassing <a href=\"https://www.benzinga.com/calendars/earnings\" rel=\"noreferrer noopener\" target=\"_blank\">consensus estimates</a> of $2.35, a jump from $1.57 reported a year ago.</p><!--/$--><!--$--><div class=\"min-w-[300px] w-[300px] min-h-[250px] raptive-ad-placement mx-auto overflow-hidden min-w-[300px]\"></div><!--/$--><!--$--><p class=\"block core-block\">Merck reported sales of $17.28 billion, a 4% increase year-over-year, and exceeded the analysts’ projections of $16.96 billion.</p><!--/$--><!--$--><p class=\"block core-block\"><strong><em>Also Read: <a href=\"https://www.benzinga.com/markets/biotech/25/10/48472199/mercks-new-cancer-therapy-combo-shows-significant-edge-over-rivals-in-renal-cancer\" rel=\"noreferrer noopener\" target=\"_blank\">Merck’s New Cancer Therapy Combo Shows Significant Edge Over Rivals In Renal Cancer</a></em></strong></p><!--/$--><!--$--><h2 class=\"wp-block-heading\">Segment And Drug Performance</h2><!--/$--><!--$--><p class=\"block core-block\">The pharmaceutical segment recorded $15.61 billion in sales, up 4% year over year, driven by growth in oncology, cardiovascular, and diabetes, partially offset by declines in vaccines, virology, and immunology.</p><!--/$--><!--$--><div class=\"sc-eQzVdq kfhAgV\"></div><!--/$--><!--$--><p class=\"block core-block\">The Animal Health segment’s revenue of $1.62 billion increased 9% year-over-year, primarily driven by the performance of livestock products.</p><!--/$--><!--$--><p class=\"block core-block\">Keytruda, an immunotherapy for cancer, generated $8.14 billion in global sales, representing a 10% year-over-year increase, driven by continued strong demand <a href=\"https://www.benzinga.com/pressreleases/25/10/b48521501/merck-co-inc-rahway-n-j-usa-announces-third-quarter-2025-financial-results\" rel=\"noreferrer noopener\" target=\"_blank\">from metastatic indications</a> worldwide.</p><!--/$--><!--$--><p class=\"block core-block\">GARDASIL and GARDASIL 9, vaccines to prevent HPV-related diseases, generated $1.75 billion in sales, down 24% compared to last year. The company cited lower demand in China.</p><!--/$--><!--$--><p class=\"block core-block\">The diabetes franchise, led by JANUVIA and JANUMET, increased 29% to $624 million.</p><!--/$--><!--$--><div class=\"nativo-placement-in-content-ap\"></div><!--/$--><!--$--><p class=\"block core-block\">Newer products, including Winrevair sales, a therapy for pulmonary arterial hypertension (a rare heart-lung condition), saw sales jump by 141% to 360 million.</p><!--/$--><!--$--><h2 class=\"wp-block-heading\">Guidance </h2><!--/$--><!--$--><p class=\"block core-block\">Merck raised its fiscal 2025 adjusted earnings guidance <a href=\"https://www.benzinga.com/markets/earnings/25/07/46692220/merck-ceo-sees-minimal-eu-tariffs-impact-warns-of-gardasil-challenges\" rel=\"noreferrer noopener\" target=\"_blank\">from $8.87-$8.97 per share</a> to $8.93-$8.98 compared to the Wall Street estimate of $8.91.</p><!--/$--><!--$--><div class=\"min-w-[300px] w-[300px] min-h-[250px] raptive-ad-placement mx-auto overflow-hidden min-w-[300px]\"></div><!--/$--><!--$--><p class=\"block core-block\">The U.S. drug giant narrowed its fiscal 2025 sales outlook from $64.3 billion to $65.3 billion to $64.5 billion to $65 billion, compared to the consensus estimate of $64.66 billion.</p><!--/$--><!--$--><h2 class=\"wp-block-heading\">M&amp;A</h2><!--/$--><!--$--><p class=\"block core-block\">A Merck executive on the company’s conference call stated that the company continues to focus on a potential deal size of $1 billion to $15 billion and is willing to go larger.</p><!--/$--><!--$--><div class=\"min-w-[300px] w-[300px] min-h-[250px] raptive-ad-placement mx-auto overflow-hidden min-w-[300px]\"></div><!--/$--><!--$--><p class=\"block core-block\"><strong>MRK Price Action:</strong> Merck &amp; Co shares were up 0.07% at $86.64 at the time of publication on Thursday, <a href=\"https://www.benzinga.com/pro/\" rel=\"noreferrer noopener\" target=\"_blank\">according to Benzinga Pro data</a>.</p><!--/$--><!--$--><!--/$--><!--$--><ul class=\"wp-block-list\">\n<li><strong><em><a href=\"https://www.benzinga.com/node/48529099\" rel=\"noreferrer noopener\" target=\"_blank\">Mounjaro And Zepbound Power Eli Lilly’s 54% Revenue Jump In Q3, Hikes 2025 Forecast</a></em></strong></li>\n</ul><!--/$--><!--$--><p class=\"block core-block\"><em>Photo by Tada Images via Shutterstock</em></p><!--/$--><!--$--><div><div><div class=\"bz-campaign bz-campaign-bottom-48535333\" data-nosnippet=\"true\"><div class=\"sc-c014f608-0 kUPEDz skeleton min-h-[inherit] animate-pulse variant\" role=\"status\"><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div></div><div class=\"flex sm:hidden flex-col\"><div class=\"sc-c014f608-0 kUPEDz skeleton min-h-[inherit] animate-pulse variant\" role=\"status\"><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div></div></div></div></div></div><!--/$--></div></div>",
            "image": "https://www.benzinga.com/files/images/story/2025/10/30/South-San-Francisco--Ca--Usa---May-1--20.jpeg",
            "link": "https://www.benzinga.com/markets/earnings/25/10/48535333/merck-ready-for-larger-than-15-billion-deals-raises-annual-profit-outlook",
            "pub_date": "2025-10-31 00:24:17",
            "source": "benzinga",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "69038fadecb8a70001459f1a",
            "title": "Nvidia&#39;s $5 Trillion Milestone Turns These AI ETFs Into Hot Trades",
            "description": "<div><div class=\"sc-fxwyg khStwV\"><!--$--><p class=\"block core-block\"><strong>NVIDIA Corp.</strong>‘s (NASDAQ:<a class=\"ticker\" href=\"https://www.benzinga.com/quote/NVDA\" target=\"_blank\">NVDA</a>) market cap just did what no company in history has: crossed the $5 trillion threshold, and ETF investors are racing to catch the wave. </p><!--/$--><!--$--><p class=\"block core-block\">The milestone, fueled by blockbuster AI deals and surging chip demand, has turned <a href=\"https://www.benzinga.com/etfs\" target=\"_blank\">semiconductor ETFs</a> into the hottest trade in town.</p><!--/$--><!--$--><div class=\"min-w-[300px] w-[300px] min-h-[250px] raptive-ad-placement mx-auto overflow-hidden min-w-[300px]\"></div><!--/$--><!--$--><ul class=\"wp-block-list\">\n<li><strong>Nvidia is up in double digits in the past 5 days.<a href=\"https://www.benzinga.com/quote/nvda\" target=\"_blank\"> Track its prices in real time</a>.</strong></li>\n</ul><!--/$--><!--$--><h2 class=\"wp-block-heading\"><strong>ETFs Riding The Nvidia Supercycle</strong></h2><!--/$--><!--$--><p class=\"block core-block\">The rally has rippled across funds with heavy Nvidia exposure. The <strong>VanEck Semiconductor ETF</strong> (NASDAQ:<a class=\"ticker\" href=\"https://www.benzinga.com/quote/SMH\" target=\"_blank\">SMH</a>), which counts Nvidia as its top holding, jumped as investors priced in stronger AI infrastructure demand. The fund ended Wednesday with 1.5% gains after surging even higher earlier in the day. The <strong>Strive U.S. Semiconductor ETF</strong> (NYSE:<a class=\"ticker\" href=\"https://www.benzinga.com/quote/SHOC\" target=\"_blank\">SHOC</a>) and <strong>VanEck Fabless Semiconductor ETF</strong> (NASDAQ:<a class=\"ticker\" href=\"https://www.benzinga.com/quote/SMHX\" target=\"_blank\">SMHX</a>) also climbed 2% on Wednesday as Nvidia hit the record-breaking milestone, benefiting from the dominance of NVIDIA in the fabless chip segment.</p><!--/$--><!--$--><div class=\"sc-gQfuga iaHpuj\"></div><!--/$--><!--$--><p class=\"block core-block\">Options-based funds, such as the <strong>YieldMax Target 12 Semiconductor Option Income ETF</strong> (NYSE:<a class=\"ticker\" href=\"https://www.benzinga.com/quote/SOXY\" target=\"_blank\">SOXY</a>), have found fresh popularity with yield-starved investors looking for income without missing out on upside. </p><!--/$--><!--$--><p class=\"block core-block\">The ETF momentum is partly a reflection of how Nvidia has become the benchmark for AI growth, a sentiment play that's spreading to the entire semiconductor complex.</p><!--/$--><!--$--><h2 class=\"wp-block-heading\"><strong>Supercomputers, Self-Driving Cars and A Supply Crunch</strong></h2><!--/$--><!--$--><p class=\"block core-block\">In all, Nvidia’s rally began a week ago with a barrage of announcements at its GTC event in Washington, D.C. The company announced collaborations with the <strong>U.S. Department of Energy </strong>on seven new AI supercomputers, <strong>Uber Technologies Inc</strong> (NYSE:<a class=\"ticker\" href=\"https://www.benzinga.com/quote/UBER\" target=\"_blank\">UBER</a>) on <a href=\"https://www.benzinga.com/markets/tech/25/10/48519612/amid-nvidia-partnership-uber-ceo-dara-khosrowshahi-makes-bold-autonomous-driving-prediction-should-we-allow-humans-to-drive\" target=\"_blank\">100,000 autonomous vehicles through 2027</a>, and <strong>Eli Lilly And Co</strong> (NYSE:<a class=\"ticker\" href=\"https://www.benzinga.com/quote/LLY\" target=\"_blank\">LLY</a>) and <strong>Nokia Oyj </strong>(NYSE:<a class=\"ticker\" href=\"https://www.benzinga.com/quote/NOK\" target=\"_blank\">NOK</a>) on biotech and 6G initiatives, respectively.</p><!--/$--><!--$--><div class=\"nativo-placement-in-content-ap\"></div><!--/$--><!--$--><p class=\"block core-block\">At the same time, <strong>SK Hynix</strong>, a critical Nvidia memory supplier, said its entire 2026 output is already sold out, pointing to an extended AI-driven chip boom. That gives the semiconductor trade long-term legs, reinforcing ETF investors’ conviction.</p><!--/$--><!--$--><h2 class=\"wp-block-heading\"><strong>Trade Truce Tailwinds?</strong></h2><!--/$--><!--$--><p class=\"block core-block\">With a U.S.–China trade thaw post a <a href=\"https://www.benzinga.com/news/politics/25/10/48519309/trump-concludes-amazing-meeting-with-xi-jinping-teases-pretty-soon-trade-deal\" target=\"_blank\">meeting between U.S. President <strong>Donald Trump</strong> and Chinese President <strong>Xi Jinping</strong></a>, Nvidia could regain access to its biggest overseas market. An easing of export restrictions would further strengthen the earnings outlook for the chipmaker and ETFs hitched to its success.</p><!--/$--><!--$--><div class=\"min-w-[300px] w-[300px] min-h-[250px] raptive-ad-placement mx-auto overflow-hidden min-w-[300px]\"></div><!--/$--><!--$--><p class=\"block core-block\">Nvidia’s $5 trillion valuation underlines how strongly the AI story has merged with ETF investing. For as long as GPUs remain at the heart of the global race in AI, semiconductor ETFs might keep rewriting their own record books — one trillion at a time.</p><!--/$--><!--$--><div><div><div class=\"bz-campaign bz-campaign-bottom-48535168\" data-nosnippet=\"true\"><div class=\"sc-c014f608-0 kUPEDz skeleton min-h-[inherit] animate-pulse variant\" role=\"status\"><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div></div><div class=\"flex sm:hidden flex-col\"><div class=\"sc-c014f608-0 kUPEDz skeleton min-h-[inherit] animate-pulse variant\" role=\"status\"><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div></div></div></div></div></div><!--/$--><!--$--><!--/$--><!--$--><ul class=\"wp-block-list\">\n<li><strong><a href=\"https://www.benzinga.com/markets/tech/25/10/48528320/nvidia-effect-key-suppliers-have-already-sold-out-ai-memory-chips-for-2025\" target=\"_blank\">Nvidia Effect: Key Suppliers Have Already Sold Out AI Memory Chips For 2025</a></strong></li>\n</ul><!--/$--><!--$--><p class=\"block core-block\"><em>Photo: Mehaniq via Shutterstock</em></p><!--/$--></div></div>",
            "image": "https://www.benzinga.com/files/images/story/2025/10/30/Kyiv--Ukraine---January-29--2025-Nvidia-.jpeg",
            "link": "https://www.benzinga.com/etfs/sector-etfs/25/10/48535168/nvidias-5-trillion-milestone-turns-these-ai-etfs-into-hot-trades",
            "pub_date": "2025-10-31 00:17:52",
            "source": "benzinga",
            "kind": 1,
            "language": "en"
        }
    ]
}